IL5: Interleukin-5
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Homodimeric cytokine expressed predominantly by T-lymphocytes and NK cells that plays an important role in the survival, differentiation, and chemotaxis of eosinophils.
- Drugs that act on it: 3
- Approved: 2
- In phases 1 to 3: 1
- Sponsors: 2
Who Is On It, and How Far Along
Every drug ChEMBL records acting on IL5, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Interleukin-5 inhibitor.| Mepolizumab | Approved | GSK | Antibody | Inhibitor | — | 35 | — |
| Reslizumab | Approved | Teva Pharmaceutical Industries | Antibody | Inhibitor | — | 3 | Boxed warning |
| Depemokimab | Phase 3 | GSK | Antibody | Inhibitor | — | 11 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 17 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Asthma
- 0.73
- Chronic rhinosinusitis
- 0.47
- Airway obstruction
- 0.47
- Nasal cavity polyp
- 0.46
- Nasal polyposis
- 0.41
- Chronic rhinosinusitis with nasal polyps
- 0.41
- Childhood onset asthma
- 0.38
- Atopic eczema
- 0.38
- Vasculitis
- 0.38
- Eosinophilic granulomatosis with polyangiitis
- 0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1169600, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P05113, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets